It has been FDA-approved for a variety of cancers including metastatic colorectal cancer (first line therapy, 2004/second line therapy, 2006), advanced nonsquamous non-small-cell lung cancer in combination with carboplatin/paclitaxel chemotherapy (first line therapy, 2006), glioblastoma (second line therapy, 2009), metastatic RCC (2009), metastatic HER2-negative breast cancer (2011), and metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy (2013). This evidence concerns the gene ERBB2 and cancer.